問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Division of Radiology

Division of General Internal Medicine

Division of Others-

更新時間:2023-09-19

張允中
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

28Cases

2025-02-19 - 2029-05-04

Phase IV

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2008-11-01 - 2011-05-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2021-10-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting2Sites

Terminated6Sites

2021-06-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting9Sites

Recruiting2Sites

2020-07-01 - 2027-12-31

Phase III

Active
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
  • Condition/Disease

    HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting

  • Test Drug

    Trastuzumab deruxtecan (ENHERTUR)

Participate Sites
8Sites

Recruiting8Sites

2019-01-01 - 2026-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-12-01 - 2027-12-31

Phase II

Active
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    injection

Participate Sites
10Sites

Recruiting10Sites

1 2 3